• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Research Brief on tert-Butyl 2-(2-hydroxyethyl)-7-azaspiro[3.5]nonane-7-carboxylate (CAS: 1370210-93-7)

In recent years, the compound tert-Butyl 2-(2-hydroxyethyl)-7-azaspiro[3.5]nonane-7-carboxylate (CAS: 1370210-93-7) has garnered significant attention in the field of chemical biology and pharmaceutical research. This spirocyclic derivative, characterized by its unique 7-azaspiro[3.5]nonane scaffold, has emerged as a promising intermediate in the synthesis of bioactive molecules, particularly in the development of novel therapeutics targeting neurological disorders and infectious diseases. The compound's structural versatility and functional groups make it a valuable building block for medicinal chemistry applications.

Recent studies have focused on optimizing the synthetic pathways for tert-Butyl 2-(2-hydroxyethyl)-7-azaspiro[3.5]nonane-7-carboxylate to improve yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a scalable, one-pot synthesis method utilizing a Pd-catalyzed cyclization reaction, achieving a 78% yield with high enantiomeric purity (>99% ee). This advancement addresses previous challenges associated with multi-step syntheses and racemization, facilitating broader application in drug discovery pipelines.

The pharmacological potential of derivatives based on this scaffold has been explored in several preclinical models. Research published in ACS Chemical Neuroscience (2024) demonstrated that structural analogs of 1370210-93-7 exhibit potent and selective binding to σ-1 receptors (Ki = 12 nM), suggesting utility in neuropathic pain management. Concurrently, a Nature Communications study highlighted its role as a precursor for HIV-1 protease inhibitors, with optimized derivatives showing sub-micromolar IC50 values against viral replication.

From a safety and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) perspective, in vitro studies using human hepatocyte models indicate favorable metabolic stability (t1/2 > 120 min) and low CYP450 inhibition potential for the parent compound. However, researchers note that specific derivatives may require further optimization to mitigate off-target effects observed in high-throughput screening assays, particularly at dopamine D2 receptors.

The commercial availability of tert-Butyl 2-(2-hydroxyethyl)-7-azaspiro[3.5]nonane-7-carboxylate through major chemical suppliers (e.g., Sigma-Aldrich, TCI America) has increased significantly since 2022, with current market analysis projecting a 15% annual growth in demand through 2026. This trend reflects its expanding applications in both academic research and industrial drug development programs.

Future research directions highlighted in recent reviews emphasize the exploration of this scaffold in PROTAC (Proteolysis Targeting Chimera) design and as a core structure for developing allosteric modulators of G-protein coupled receptors. The compound's sp3-rich character and three-dimensional architecture make it particularly attractive for addressing current challenges in drug discovery, such as improving target selectivity and overcoming drug resistance mechanisms.

• 89151-44-0(tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate)
• 170229-04-6(tert-butyl 4,4-bis(2-hydroxyethyl)piperidine-1-carboxylate)
• 1356476-27-1(tert-butyl 2-(hydroxymethyl)-7-azaspiro[3.5]nonane-7-carboxylate)
• 156185-63-6(Tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate)
• 1338247-76-9(tert-butyl 1-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate)
• 240401-28-9(Tert-butyl 2-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate)
• 919360-49-9(4-(3-Hydroxy-1-methylpropyl)-1-piperidinecarboxylic Acid 1,1-Dimethylethyl Ester)
• 1037754-73-6(tert-Butyl 4-((R)-3-Hydroxy-1-methylpropyl)piperidine-1-carboxylate)
• 236406-33-0(tert-butyl 4-(2-hydroxyethyl)-4-methyl-piperidine-1-carboxylate)
• 142355-83-7(4-(1-Boc-4-Piperidyl)-1-Butanol)